Evidence map›Paper›PMID 38631824›Full record

SynthesisBMJ open2024

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials.

Huzaifa Ahmad Cheema, Uzair Jafar, Abia Shahid, Waniyah Masood, Muhammad Usman, Alaa Hamza Hermis, Muhammad Arsal Naseem, Syeda Sahra, Ranjit Sah, Ka Yiu Lee

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Colchicine-The Divine Medicine against COVID-19.Journal of personalized medicine · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Huzaifa Ahmad Cheema *Department of Medicine, King Edward Medical University, Lahore, Pakistan.ORCID 0000-0001-6783-7137
Uzair Jafar *Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Abia ShahidDepartment of Medicine, King Edward Medical University, Lahore, Pakistan.
Waniyah MasoodDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Muhammad UsmanDepartment of Medicine, King Edward Medical University, Lahore, Pakistan.
Alaa Hamza HermisNursing College, Al-Mustaqbal University, 51001 Hillah, Babylon, Iraq.
Muhammad Arsal NaseemDepartment of Medicine, King Edward Medical University, Lahore, Pakistan.
Syeda SahraDepartment of Infectious Diseases, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Ranjit SahDepartment of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune 411018, Maharashtra, India.
Ka Yiu LeeSwedish Winter Sports Research Centre, Department of Health Sciences, Mid Sweden University, Sundsvall, Sweden kyle.lee@miun.se.ORCID 0000-0001-5577-0940
King Edward Medical University · PKDow University of Health Sciences · PKDr. D. Y. Patil Medical College, Hospital and Research Centre · INMid Sweden University · SEUniversity of Babylon · IQUniversity of Oklahoma Health Sciences Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe conducted an updated systematic review and meta-analysis to investigate the effect of colchicine treatment on clinical outcomes in patients with COVID-19.

designSystematic review and meta-analysis. DATA SOURCES: We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023. ELIGIBILITY CRITERIA: All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded. DATA EXTRACTION AND SYNTHESIS: We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures.

resultsWe included 23 RCTs (28 249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95% CI 0.93 to 1.05; I

conclusionsThe results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population. PROSPERO REGISTRATION NUMBER: CRD42022369850.

Indexed as

ColchicineCOVID-19COVID-19 Drug TreatmentRandomized Controlled Trials as TopicSARS-CoV-2HumansTreatment OutcomeColchicineCLINICAL PHARMACOLOGYCOVID-19VIROLOGY

Identifiers

PMID38631824
PMCPMC11029412
OpenAlexW4394893933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.